[1] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822. [2] Deitzel JM, Kleinmeyer JD, Hirvonen JK, et al. Controlled deposition of electrospun poly(ethylene oxide) fibers. Polymer. 2000;42:8163-8170.[3] Zussman E, Burman M, Yarin AL, et al. Tensile deformation of electrospun nylon-6,6 nanofibers. Journal of Polymer Science B: Polymer Physics. 2006;44:1482-1489.[4] Auras R, Harte B, Selke S. An overview of polylactides as packaging materials. Macromol Biosci. 2004;4(9):835-864. [5] 石淑先,夏宇正,郭祖鹏,等.聚D,L-乳酸的合成及表征[J].弹性体,2002,12(6):10-13. [6] Drumright RE, Gruber PR, Henton DE. Polylactic acid technology. Advanced Materials. 2000;12:1841-1846.[7] Pelouze J. Memoire sure l'acide lactique. Annual Chimie. 1845;3(13):257-268.[8] Carothers WH, Dorough GL, Van Natta FJ. Studies of polymerization and ring formation. X. The reversible polymerization of six-membered cyclic ester. Journal of the American Chemical Society. 1932;54:761-772. [9] Lowe CE. Preparation of high molecular weight polyhydroxyacetic ester. US Patent, 2668162,1954.[10] Yolles S, Leaffe T, Ward L, et al. Controlled release of biologically active drugs. Bull Parenter Drug Assoc. 1976; 30(6):306-312. [11] Uchida T, Yoshida K, Ninomiya A, et al. Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Chem Pharm Bull (Tokyo). 1995;43(9): 1569-1573. [12] Cao X, Schoichet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials. 1999;20(4):329-339. [13] 郭圣荣.医药用生物降解性高分子材料[M].北京:化学工业出版社,2003.42-43.[14] 中国知网.中国学术期刊总库[DB/OL].2012-11-28. https://www.cnki.net [15] 冯芳.5-FU载药纳米微粒的制备、表征及体外实验[D].甘肃:兰州大学,2009:1-46.[16] 毕秀增,潘伟华,南开辉,等.5-氟尿嘧啶缓释剂制备及体外释药性能比较[J].中国组织工程研究,2012,16(8):1430-1434.[17] 周志敏.抗肿瘤药物表阿霉素缓释制剂及聚乳酸自组装行为的研究[D].福建:厦门大学,2006:1-82.[18] 蔡敏娴,陈志奎,林礼务,等.载多烯紫杉醇聚乳酸-羟基乙酸微球的制备、表征及其药物稳定性[J].中国组织工程研究与临床康复,2010,14(21):3856-3860.[19] 叶社房,侯振清,周志敏,等.植入型表阿霉素缓释药膜的制备及体内抑瘤活性[J].中国生物医学工程学报,2008,27(4): 586-590.[20] 刘杰,徐伟华,金成,等.载阿霉素PLGA纳米微球的制备及性质研究[J].现代生物医学进展,2010,10(24):4661-4663.[21] 胡庆军.聚DL-乳酸在HA复合材料与药物缓释中的应用[D].湖北:华中科技大学,2006:1-59.[22] 刘娟,肖丽英,李伟,等.可吸收聚乳酸-替硝唑抗菌缓释剂体外药物释放效果的测定[J].华西口腔医学杂志,2005,23(3):237-239.[23] 王哲,张秀梅,倪宏哲,等.聚乳酸载阿奇霉素微球包裹和体外释放行为[J].中国生物医学工程学报,2009,28(2):314-316.[24] 刘江涛,王永清,夏侃,等.异烟肼聚乳酸缓释体的制备及体内外释药特性[J].中国脊柱脊髓杂志,2008,18(4):290-293.[25] 叶向阳,孙湘,贾会文,等.利福平/聚乳酸-聚羟基乙酸缓释微球的制备及特性[J].中国组织工程研究与临床康复,2011,15(51): 9608-9612.[26] 胡春晖.利福平微球-原位凝胶复合缓释载体的研究[D].北京:北京协和医学院,2011:1-109.[27] 肖莉,张韵慧,崔颖,等.尼莫地平聚乳酸缓释微球的制备及其药剂学性质[J].中国医院药学杂志,2008,28(3):194-198.[28] 刘国磊,王帅,王静,等.长春西汀聚乳酸-聚乙醇酸缓释微球的研制[J].中国药房,2012,23(13):1203-1206.[29] 张敏.洛伐他汀聚乳酸微球的制备及释药特性[D].北京:北京化工大学,2011:1-89.[30] 胡婧.羟基喜树碱缓释片脑内植入治疗脑胶质瘤的研究[D].重庆:第三军医大学,2008:1-68.[31] 索新,刘伟,郭永川,等.可生物降解高分子超细纤维PLA药物缓释体作用于脑胶质瘤的体外研究[J].中国微侵袭神经外科杂志, 2006, 11(12):558-561.[32] Asmus LR, Tille JC, Kaufmann B, et al. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J Control Release. 2012;165(3):199-206. [33] Ranjan AP, Mukerjee A, Helson L, et al. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnology. 2012; 10:38. [34] Asmus LR, Kaufmann B, Melander L, et al. Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer. Eur J Pharm Biopharm. 2012;81(3):591-599. [35] Agrawal R, Shanavas A, Yadav S, et al. Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel. J Biomed Nanotechnol. 2012;8(1):19-28. [36] Parker T, Davé V, Falotico R, et al. Control of cilostazol release kinetics and direction from a stent using a reservoir-based design. J Biomed Mater Res B Appl Biomater. 2012;100(3):603-610. [37] Asmus LR, Gurny R, Möller M. Solutions as solutions--synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulatesustained-release parenterals. Eur J Pharm Biopharm. 2011;79(3):584-591. [38] Zhan W, Zhang X. Preparation of sustained release microspheres containing extracts from Caulis sinomenii with polylactic acid and their release property in vitro. Zhongguo Zhong Yao Za Zhi. 2010;35(16):2142-2145. [39] Wang TW, Wu Y, Li MJ, et al. Preparation and drug release property of paclitaxel nanoparticles. Zhong Yao Cai. 2009; 32(9): 1447-1449. [40] Kang C, Yuan X, Zhong Y, et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. Technol Cancer Res Treat. 2009;8(1):61-70. [41] Gao H, Ping Q, Gu Y. Fabrication, characterization and drug release characteristics of drug loaded poly (L-lactic acid) fiber. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008;25(4): 870-873. [42] Rothen-Weinhold A, Besseghir K, Vuaridel E, et al. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur J Pharm Biopharm. 1999;48(2):113-121. [43] Pardridge WM. Drug targeting to the brain. Pharm Res. 2007; 24(9):1733-1744. [44] Mariette B, Coudane J, Vert M. Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix. J Control Release. 2005;106(3): 253-262. [45] Yamagata T, Morishita M, Kavimandan NJ, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release. 2006;112(3):343-349. [46] Edelman ER, Langer R. Optimization of release from magnetically controlled polymeric drug release devices. Biomaterials. 1993;14(8):621-626. |